Background Image
Table of Contents Table of Contents
Previous Page  164 / 1498 Next Page
Information
Show Menu
Previous Page 164 / 1498 Next Page
Page Background

Conclusions – Role of RIT in Follicular lymphoma

RIT simple and effective treatment; most active drug in NHL,

unique mechanism of action

Effective (high response rate, durable remission) and underused single

treatment in relapsed and rituximab refractory disease

Patients in

90

Y-ibritumomab arm had a greater than 5-year advantage in

time to next treatment in FIT trial as consolidation

Phase II data as single agents Zevalin RIT in untreated follicular lymphoma

show high response rates and durable remission

Novel Radioimmunconjugates are being developed but pathways to

registration and routine clinical use are challenging.